← Back to Search

Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET Scan for Cancer

N/A

Waitlist Available

Led By Jeffrey Wong

Research Sponsored by City of Hope Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up at 1 and 3 months post study drug infusion

Awards & highlights

Study Summary

This trial uses a radioactive antibody to help detect cancer cells in patients with high levels of a protein called CEA. PET scans may help find and diagnose cancer that may not be detected by other methods.

Who is the study for?

This trial is for adults with certain types of cancer that produce a marker called CEA. They must have completed any previous treatments at least 2 weeks before, agree to use contraception, and not be pregnant or breastfeeding. People with uncontrolled illnesses or allergies to similar drugs are excluded.Check my eligibility

What is being tested?

The study tests a diagnostic procedure using Copper Cu 64 anti-CEA monoclonal antibody M5A PET scans to detect cancers expressing the CEA marker more effectively than standard methods.See study design

What are the potential side effects?

Potential side effects may include allergic reactions related to the copper Cu 64 anti-CEA monoclonal antibody M5A compound. Specific side effects are not listed but could relate to immune responses due to exposure.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ at 1 and 3 months post study drug infusion

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~at 1 and 3 months post study drug infusion

This trial's timeline: 3 weeks for screening, Varies for treatment, and at 1 and 3 months post study drug infusion for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Tumor Uptake of 64Cu-DOTA-hT4.66-M5A at Day 1

Tumor Uptake of 64Cu-DOTA-hT4.66-M5A at Day 2

Secondary outcome measures

Number of Participants With Human Anti-human Antibody (HAHA) Positive Response to 64Cu Labeled M5A Antibody

The Average Increase of Tumor-to-blood (T:B) Ratio From Day 1 to Day 2

Trial Design

1Treatment groups

Experimental Treatment

Group I: Diagnostic (copper Cu 64 anti-CEA monoclonal antibody M5A PET)Experimental Treatment5 Interventions

Patients receive copper Cu 64 anti-CEA monoclonal antibody M5A IV on day 0 and then undergo PET on day 1 and day 2.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

positron emission tomography

2010

Completed Phase 2

~1370

radionuclide imaging

2006

Completed Phase 1

~1120

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

City of Hope Medical CenterLead Sponsor

565 Previous Clinical Trials

1,921,440 Total Patients Enrolled

National Cancer Institute (NCI)NIH

13,654 Previous Clinical Trials

40,933,133 Total Patients Enrolled

Jeffrey WongPrincipal InvestigatorCity of Hope Medical Center

2 Previous Clinical Trials

17 Total Patients Enrolled

Media Library

Cu 64 anti-CEA monoclonal antibody M5A IV Clinical Trial Eligibility Overview. Trial Name: NCT02293954 — N/A

Cancer Research Study Groups: Diagnostic (copper Cu 64 anti-CEA monoclonal antibody M5A PET)

Cancer Clinical Trial 2023: Cu 64 anti-CEA monoclonal antibody M5A IV Highlights & Side Effects. Trial Name: NCT02293954 — N/A

Cu 64 anti-CEA monoclonal antibody M5A IV 2023 Treatment Timeline for Medical Study. Trial Name: NCT02293954 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there other investigations concerning the effects of Cu 64 anti-CEA monoclonal antibody M5A IV?

"Presently, seven clinical trials utilizing Cu 64 anti-CEA monoclonal antibody M5A IV are underway with one at Phase 3. With the majority of studies taking place in Saint Louis, Missouri, a total of 16 sites have been identified to handle these investigations."

Answered by AI

For what afflictions has Cu 64 anti-CEA monoclonal antibody M5A IV proven to be beneficial?

"Copper-64 anti-CEA monoclonal antibody M5A IV can be utilized to manage trace element deficiencies, an individual's weight exceeding 40 kilograms, as well as Intrauterine Device (IUD) therapy."

Answered by AI

Are there still opportunities to join this scientific investigation?

"Sadly, this medical trial has concluded its patient recruitment phase. It was initially posted on the 11th of November 2015 and had its last update on October 20th 2022. However, other trials that may interest you include 5126 studies for cancer of the gallbladder and 7 clinical investigations related to Cu 64 anti-CEA monoclonal antibody M5A IV actively seeking participants."

Answered by AI

What is the cap on enrolment for this clinical trial?

"This study is not presently accepting participants. It was first posted in November of 2015 and the latest update occurred on October 20th, 2022. Alternately, right now there are 5126 trials that require gallbladder cancer patients and seven studies seeking enrolment for Cu 64 anti-CEA monoclonal antibody M5A IV."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer

2015. "Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02293954.

All > Intrahepatic Cholangiocarcinoma > Thyroid Cancer